Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that five abstracts, describing FOLOTYN^® (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52^nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

“Identification of an Active, Well-Tolerated Dose of Pralatrexate in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma (CTCL): Results of a Multicenter Dose-Finding Study”

"At ASH, new and updated analyses expand our understanding of the clinical data for FOLOTYN in patients with T-cell lymphoma, including data from the pivotal Phase 2 PROPEL study in relapsed or refractory peripheral T-cell lymphoma and transformed mycosis fungoides, as well as updated results from the Phase 1 dose-finding study in relapsed or refractory cutaneous T-cell lymphoma," said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics. "Allos is committed to exploring the potential of FOLOTYN to address the treatment needs for patients with devastating diseases, such as T-cell lymphoma. We are pleased that the American Society of Hematology has chosen these important findings to be included in this year's meeting and look forward to sharing the full results with the hematology community in December."

FOLOTYN, a folate analogue metabolic inhibitor, is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

FOLOTYN abstract details are as follows:

Abstract Title: "Pralatrexate is an Effective Treatment for Heavily Pretreated Patients with Relapsed or Refractory Transformed Mycosis Fungoides (tMF)"
First Author: Francine Foss, MD, Yale Medical Center
Abstract Number: 1762 (Poster Board I-742)
Location: Hall A3/A4 - Orange County Convention Center
Presentation Date/Time: Saturday, December 4, 5:30-7:30 p.m.

Abstract Title: "Pralatrexate is Effective as Second-line Treatment Following Cyclophosphamide/Doxorubicin/ Vincristine/Prednisone (CHOP) Failure in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma"
First Author: Andrei Shustov, MD, Seattle Cancer Care Alliance
Abstract Number/Location: Publication Only

Abstract Title: "Pralatrexate is Effective in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-based Regimens"
First Author: Andrew Goy, MD, John Theurer Cancer Center at Hackensack University Medical Center
Abstract Number: 1753 (Poster Board I-733)
Location: Hall A3/A4 - Orange County Convention Center
Presentation Date/Time: Saturday, December 4, 5:30-7:30 p.m.

Abstract Title: "Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma"
First Author: Owen O'Connor, MD, New York University Medical Center
Abstract Number/Location: Publication Only

Abstract Title: "Identification of an Active, Well-Tolerated Dose of Pralatrexate in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma (CTCL): Results of a Multicenter Dose-Finding Study"
First Author: Steven Horwitz, MD, Memorial Sloan-Kettering Cancer Center
Abstract Number: 2800 (Poster Board II-680)
Location: Hall A3/A4 - Orange County Convention Center
Presentation Date/Time: Sunday, December 5, 6:00-8:00 p.m.